§ COMPOUND PROFILE · INDEPENDENT RESEARCH161 TESTS · AVG 99.64% · 219 SHOPS
◆ COMPOUND · WEIGHT LOSS & METABOLIC
Weight Loss & Metabolic

Cagrilintide

Long-acting amylin receptor agonist developed by Novo Nordisk, researched for appetite regulation and weight management alongside semaglutide (CagriSema).

Peptigrity tracks Cagrilintide across 219 shops with 161 independent lab tests and an average HPLC purity of 99.64%.

Avg. HPLC purity99.64%
Lab tests on file161
Shops selling219

Lab test results

161 tests · AVG 99.64%
◆ CROSS-SHOP COMPARISON · SORTED BY DATE12 of 161 SHOWN
Date
Shop
Purity
Qty (labeled → tested)
Endotoxins
Lab
May 6, 2026
99.06%
10mg9.31mg-6.9%
-
Apr 22, 2026
99.69%
5mg5.23mg+4.6%
NMT 0.05 EU/mL
Apr 8, 2026
99.89%
15mg13.72mg-8.5%
-
Apr 8, 2026
99.90%
5mg5.16mg+3.2%
-
Mar 25, 2026
99.90%
5mg5.68mg+13.6%
≤ 0.5 EU/mL (Pass)
Mar 20, 2026
99.85%
5mg5.28mg+5.6%
-
Mar 20, 2026
99.95%
10mg10.98mg+9.8%
-
Mar 20, 2026
99.95%
10mg10.98mg+9.8%
-
Mar 20, 2026
99.78%
10mg10.49mg+4.9%
2025-08-06
Mar 19, 2026
99.76%
10mg10.14mg+1.4%
<0.05 EU/mL
Mar 15, 2026
99.28%
10mg9.71mg-2.9%
-

Shops selling Cagrilintide

219 verified · top 6 shown

What Is Cagrilintide

Mechanism & research

Long-acting amylin receptor agonist developed by Novo Nordisk, researched for appetite regulation and weight management alongside semaglutide (CagriSema).

Cagrilintide vs other peptides

Same category · Lab-verified
Compound
Mechanism
Avg purity
Tests
Compare
Cagrilintide→ This page
Long-acting amylin receptor agonist
99.64%
161
GLP-1 / GIP / Glucagon triple-agonist
99.65%
610
GLP-1 / GIP dual-agonist
99.57%
575
GLP-1 receptor agonist
99.65%
238
Mitochondrial-derived metabolic peptide
99.43%
233
HGH fragment for lipolysis
99.21%
79
Compared on independent lab purityBrowse all Weight Loss & Metabolic

Related peptides

Same category
● COMMUNITY VERIFICATION

Have a lab test for Cagrilintide?

Every submitted test helps the community verify purity across brands. Free, fast, independent.

Submit a test →